New ETF Book by Larry Connors - Click here to read more
GAAP net income was $16.0 million, or $0.06 per diluted share, compared with $119.6 million, or $0.42 per diluted share, in the third quarter of 2008. Non-GAAP net income was $83.9 million, or $0.31 per diluted share, compared with $151.4 million, or $0.53 per diluted share, in the same period last year. Non-GAAP net income excludes purchase accounting and inventory step-up associated with the acquisition of Bayer oncology assets, and stock compensation.
GAAP and non-GAAP net income in this year's third quarter reflect the $23.7 million pre-tax cost of the temporary Allston shutdown and related remediation costs. Net income also includes the $7.0 million pre-tax impact of a payment to acquire technology from Targeted Genetics. These expenses, along with lost Cerezyme/Fabrazyme revenue and a shift in product mix, reduced the gross margin to approximately 67 percent of revenue during the third quarter.
The company expects its 2009 non-GAAP EPS to be approximately $2.26, compared with previous guidance of $2.35 -- $2.90. This reflects the decision to write off Cerezyme work-in-process material, the cost of remediating the Allston plant, and management of customer-level inventories related to the Bayer transaction.
Genzyme generated approximately $363 million in cash from operations during the third quarter. The company continues to reinvest cash to expand its manufacturing infrastructure and repurchase shares to offset dilution. During the third quarter, Genzyme repurchased 5.5 million shares for $307 million. To date this year, the company has repurchased 7.5 million shares for $414 million, and is on track to reacquire a total of 20 million shares by May 2010, in-line with the goals of its existing three-year stock buyback program. Currently Genzyme has 274 million diluted shares outstanding.
"During the next 12 months, we will invest in our existing business and pipeline, while making changes to become stronger and build for our future," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "In particular, we will concentrate on recapturing momentum in our genetic disease business, where we will commit the resources to provide the highest level of service and support to patients and physicians."
Recovery of the Allston Plant
Genzyme has successfully re-started all six bioreactors at Allston for the production of Cerezyme and Fabrazyme. The company this month began filling vials of newly produced Cerezyme and anticipates that the product will be available for shipment starting at the end of November. Genzyme has completed the first production cycles for Fabrazyme, is preparing to begin the next, and anticipates that the first shipments of new Fabrazyme will take place in late-December. The company expects that it will be able to fully meet anticipated demand for these therapies in the first quarter of 2010.
The current limited inventory of both products is being distributed through conservation programs to help ensure that the most vulnerable patients continue to receive treatment. Clinical guidelines developed by expert physicians, patient group leaders and regulators are in place globally to help support doctors and patients in their decisions about product usage during this period.
As part of its efforts to strengthen its manufacturing operations, Genzyme has appointed a new site leader at the Allston plant, is recruiting additional executives to oversee manufacturing and quality control, and has hired third-party quality assurance and compliance experts to review Genzyme's operations.
In addition, construction continues on a new manufacturing facility for Cerezyme and Fabrazyme in Framingham, Mass. The plant is expected to be mechanically complete with all cell culture and bioreactor suites installed by the end of this year, and the first engineering runs for Fabrazyme are planned for the first half of 2010. The first FDA approval for commercial production at the plant is anticipated in 2011 for Fabrazyme, with Cerezyme to follow. This plant, which will include four 2000 L bioreactors, will provide substantial additional capacity to support the growth of the two products. Genzyme has already hired more than 100 people associated with the start-up of this facility.
Lumizyme Progress
Genzyme is also expanding manufacturing capacity for Myozyme(R) (alglucosidase alfa) / Lumizyme(TM) (alglucosidase alfa). The company has transitioned all production to its Geel, Belgium facility, where it is adding a third 4000 L bioreactor. Upon EMEA and FDA approvals of this bioreactor, the company will have the capacity to provide treatment for approximately 3,000 patients. Genzyme is actively seeking to acquire additional manufacturing capacity for Myozyme to support the longer-term growth of this product.
With the completion of the current projects in Belgium and Framingham, Genzyme will have more than quadrupled its biologics manufacturing capacity since 2004. The company is investing more than $1 billion to expand the Allston and Belgium facilities and to construct the new Framingham plant.
Genzyme has received FDA clearance to transition U.S. patients in the Myozyme Temporary Access Program from the product produced at the 2000 L scale to that produced at the 4000 L scale. The PDUFA date for Lumizyme (the 2000 L product) is November 14. Upon approval, Genzyme plans to submit a supplemental BLA for the 4000 L process. A standard review period is four months, which would mean an FDA action date by the end of March 2010. An FDA approval would enable widespread access to the treatment for U.S. patients.
Third-Quarter Results and Pipeline Updates
Genetic Disease
Within this segment, Myozyme revenue grew to $86.0 million, compared with $76.7 million in the third quarter of 2008. European sales are continuing to re-accelerate this year following the first-quarter E.U. approval of production at the 4000 L scale, which expanded supply. Second-quarter sales were $79.3 million.
Cerezyme revenue was $93.6 million, compared with $309.3 million in the same period last year, and Fabrazyme sales were $115.2 million compared with $125.6 million last year. Revenue for both products reflects the impact of the temporary interruption in production due to the Allston remediation. Third-quarter sales of Aldurazyme(R) (laronidase) were $40.3 million, compared with $38.2 million in the third quarter of 2008.
Genzyme has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. Genzyme is accelerating this development program in an effort to bring this potential therapy to patients as quickly as possible. Currently over 35 centers in more than 20 countries are participating in these trials, and the company expects that the number of recruiting centers will continue to increase, as more sites receive regulatory approval.
Genzyme is collaborating with PTC Therapeutics Inc. on ataluren, a novel oral therapy for the treatment of genetic disorders due to nonsense mutations. A pivotal phase 2b trial of ataluren in Duchenne muscular dystrophy is fully enrolled and results are anticipated in the first half of next year. A phase 3 trial in cystic fibrosis recently began enrolling patients.
Biosurgery
Within the Biosurgery segment, sales of Synvisc(R) (hylan G-F 20) increased 30 percent to $87.5 million, from $67.5 million in last year's third quarter. This strong growth is being driven by the successful U.S. launch of Synvisc-One(R) (hylan G-F 20), which is exceeding expectations. The product was launched in March and now represents more than 50 percent of all U.S. Synvisc business.
Synvisc-One is the only single-injection viscosupplement approved for the treatment of osteoarthritis knee pain in the United States, and its launch has significantly improved Genzyme's market share and competitive position. By reducing the burden and cost of multiple injections, Synvisc-One is expanding the market for viscosupplementation products and extending the benefits of this therapeutic approach to a broader set of patients.
Sales of Sepra(R) products grew 15 percent to $37.8 million, from $33 million in the third quarter of 2008, with growth driven by increasing use of the Seprafilm(R) adhesion barrier in C-section and other gynecologic procedures.
Cardiometabolic and Renal
Within this segment, sales of Genzyme's sevelamer therapies, Renvela(R) (sevelamer carbonate) and Renagel(R) (sevelamer hydrochloride), were $181.7 million in the third quarter, compared with $171.0 million in the same period last year.
Genzyme has begun the launch of Renvela in Europe, following the product's approval there in June. The approval includes patients not on dialysis with serum phosphorus levels greater-than or equal to 1.78 mmol/L (5.5 mg/dL), and covers both the tablet and the powder formulations.
Genzyme launched Renvela tablets for dialysis patients in the U.S. last year, received FDA approval of the powder formulation for that indication during the third quarter, and plans to launch the new formulation next month.
Genzyme has completed enrollment in a pivotal trial of an advanced phosphate binder (APB) for patients with renal disease, and results are expected in the first quarter of next year. The APB is designed to more effectively bind phosphate for a substantial improvement in potency while maintaining all the benefits of sevelamer. The company anticipates that the APB would be approved by the time the core patent estate for sevelamer expires in 2014.
Sales of Thyrogen(R) (thyrotropin alfa for injection) were $41.7 million compared with $38.2 million during the third quarter of 2008.
The first phase 3 study of mipomersen, in patients with homozygous familial hypercholesterolemia (FH), met its primary endpoint and full results will be presented at the American Heart Association meeting next month. Enrollment is complete in the second phase 3 study of mipomersen, in patients with heterozygous FH, and results are anticipated during the first half of next year. Genzyme is collaborating with Isis Pharmaceuticals Inc. on the development of this treatment.
Hematologic Oncology
Revenue from the company's Hematologic Oncology segment more than doubled to $88.0 million, from $34.1 million in the same period last year. This increase was driven by new revenue from Leukine(R) (sargramostim), Campath(R) (alemtuzumab) and Fludara(R) (fludarabine phosphate), following the closing of the transaction with Bayer at the end of May. Revenue, however, was lower than expected as the company worked this quarter to manage inventories, integrate these products into its business across several new geographies, and hire and train new personnel to support the expanded business. Genzyme expects these activities to continue throughout the fourth quarter.
Third-quarter growth in this segment was also driven by Clolar(R) (clofarabine injection) and Mozobil(R) (plerixafor injection). Mozobil was launched in Europe following approval there in August. Genzyme is also making excellent progress in the ongoing U.S. launch of the product, and sales for the first three quarters of 2009 are tracking to the company's guidance of $40 -- $50 million for the year.
Genzyme has requested a meeting with the FDA to discuss a path forward for the potential use of Clolar in adult patients with acute myeloid leukemia, following the receipt of a complete response letter regarding the company's sNDA this month. The agency has recommended that a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication. Genzyme is conducting a randomized, placebo-controlled phase 3 trial comparing Clolar in combination with cytarabine to cytarabine alone in relapsed and refractory adult AML patients. The trial continues to exceed patient accrual expectations, and results are expected in 2011.
At the December American Society of Hematology meeting there will be 12 oral presentations on Genzyme's hematologic oncology products, including new data on expanded indications in development for Mozobil, Clolar and Campath with the potential to drive future growth. Data will be presented from a phase 3 trial of Campath's use in combination with Fludara in relapsed or refractory chronic lymphocytic leukemia patients, which recently met its primary endpoint. There will be presentations on Clolar's use in AML, non-Hodgkins lymphoma, myelodysplastic syndromes and as a conditioning regimen for bone marrow transplantation. Mozobil pharmacoeconomic data, as well as data on the product's development for use in chemosensitization, will also be presented.
Genzyme's alemtuzumab for multiple sclerosis showed a durable treatment benefit in a review of four-year phase 2 trial data, which was presented at the ECTRIMS annual meeting last month. Enrollment has been completed ahead of schedule in both phase 3 studies of the product, with results expected in 2011 and U.S. approval anticipated in 2012.
Other Revenue -- Transplant, Genetics and Diagnostics
Other revenue, which includes the company's Transplant, Genetics and Diagnostics businesses, was $208.4 million compared to $198.5 million during the third quarter of 2008.
Genetics revenue increased 12 percent to $91.9 million from $82.1 million in the same period last year, driven by volume increases from new and existing clients in the reproductive and oncology businesses.
Within the Transplant business, sales of Thymoglobulin(R) (anti-thymocyte globulin, rabbit) were $55.6 million, a 16 percent increase over $47.8 million in last year's third quarter, driven by continued geographic expansion. Construction is nearly complete on a new Thymoglobulin manufacturing facility in Lyon, France, which is intended to meet the anticipated long-term demand for the product, both for its current use and potential new indications. Pending regulatory authority approval, commercial production is anticipated to begin at the site next year. Genzyme continues to explore expanded uses for Thymoglobulin, including in Type 1 diabetes, where it is conducting a phase 2 trial in conjunction with the Immune Tolerance Network.
Operating Expenses
Genzyme's non-GAAP operating expenses (which include non-GAAP SG&A, R&D, and amortization) in the third quarter were $619.2 million, compared with $652.8 million in the third quarter of 2008. GAAP operating expenses were $657.9 million compared with $691.7 million in the same period last year. GAAP and non-GAAP operating expenses for the third quarter of 2008 included a $100 million licensing fee to PTC for ataluren.
Developing New Markets
During the third quarter, Genzyme broke ground on a new R&D facility in Beijing. The initiative is a key element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in this important market. Genzyme currently has offices in Beijing and Shanghai, and markets Synvisc, Thymoglobulin and Fludara in China. In addition, Genzyme is building its presence in India, and this year launched Renvela and Synvisc-One there. Genzyme also markets Thymoglobulin and Thyrogen in the country, has a commercial office in New Delhi, and is engaged in clinical development work.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.
With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
Conference Call Information
Genzyme will host a conference call today at 11:00 a.m. Eastern. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 203-369-0172. This call will also be Webcast live on the investor events section of www.genzyme.com. Replays of the call and the Webcast will be available until midnight on October 28, 2009.
Upcoming Events
Genzyme will host a conference call on February 17, 2010 at 11:00 a.m. Eastern to discuss financial results for the fourth quarter of 2009, and 2010 guidance. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 203-369-0261. This call will also be Webcast live on the investor events section of www.genzyme.com. Replays of the call and the Webcast will be available until midnight on February 24, 2010.
This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q4 and YE 2009 non-GAAP EPS guidance; its expectations regarding the timing of shipments of newly-produced Cerezyme and Fabrazyme and when the company anticipates being able to meet full demand for these products; its regulatory plans, timetables and expectations for approval of alglucosidase alfa produced using the 2000L scale process by the FDA, the 4000L scale process by the FDA, and the additional 4000L bioreactor by the EMEA and the FDA; its plans to increase manufacturing capacity for Cerezyme, Fabrazyme, Myozyme and Thymoglobulin, including expectations regarding the timing of receipt of regulatory approvals of the new facilities and the effect the additional capacity in Framingham, Geel and Lyon will have on Genzyme's ability to meet anticipated demand for these products; its expectations regarding the timing of receipt of clinical data and U.S. approval for alemtuzumab for MS; its plans and estimated timetables for new and next-generation product clinical trials, filings and regulatory approvals, including for Genz-112638, APB, mipomersen, and ataluren; its plans to drive future growth of Mozobil, Clolar and Campath by developing expanded indications for these products; its strategy for moving forward on Clolar in AML and the expected timing of receipt of clinical trial results; its sales expectations for oncology products; and its plans to launch the powder formulation of Renvela in the U.S. and the timing thereof. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others that: Genzyme encounters additional manufacturing problems due to mechanical failures, viral or bacterial contamination, or any other reason; Genzyme encounters further supply problems due to low product yields, or a determination by a regulatory authority that product produced at its Allston facility or any other facility cannot be released; Genzyme is unable to obtain and/or maintain regulatory approvals for its products, manufacturing processes and manufacturing facilities, including securing FDA approval for alglucosidase alfa produced at the 2000L scale in Allston and the 4000L scale in Geel on expected timeframes or at all; Genzyme is unable to file for U.S. approval for the alglucosidase alfa produced using the 4000L process within the expected timeframe due to a failure to obtain FDA approval of the product manufactured using the 2000L process, failure to secure agreement as to strategy, including its decision to file a sBLA to the 4000L BLA, or any other reason; Genzyme and its collaboration partners are unable to successfully complete clinical development of new products, including Genz-112638, mipomersen and ataluren, at all or on expected timeframes; Genzyme is unable to expand the use of current and next-generation products in existing and new indications, including Synvisc-ONE, Mozobil, alemtuzumab-MS, APB, Clolar and Campath; Genzyme is unable to manufacture its products and product candidates in a timely and cost effective manner and in sufficient quantities to meet demand; Genzyme's integration of products and development programs acquired from Bayer is more costly or time-consuming than forecasted; Genzyme is unable to maintain and enforce its intellectual property rights; Genzyme is unsuccessful in identifying and marketing to new patients; the availability and extent of reimbursement from third party payers is restrained; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the period ended June 30, 2009. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.
Genzyme(R), Cerezyme(R), Fabrazyme(R), Myozyme(R), Synvisc(R), Synvisc-One(R), Sepra(R), Seprafilm(R), Renvela(R), Renagel(R), Thyrogen(R), Mozobil(R), Clolar(R), Campath(R) and Thymoglobulin(R) are registered trademarks and Lumizyme(TM) is a trademark of Genzyme Corporation or its subsidiaries. Fludara(R) and Leukine(R) are registered trademarks licensed to Genzyme Corporation. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.
Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.
GENZYME CORPORATION (GENZ)
Consolidated Statements of Operations Three Months Ended Nine Months Ended
(Unaudited, amounts in thousands, except per share amounts) September 30, September 30,
2009 2008 2009 2008
Total revenues $ 1,057,514 $ 1,160,284 $ 3,434,895 $ 3,431,479
Operating costs and expenses:
Cost of products and services sold 359,407 285,208 1,005,742 857,851
Selling, general and administrative 367,347 331,170 1,039,436 996,861
Research and development 219,275 305,242 636,722 949,900
Amortization of intangibles 71,280 55,295 192,823 166,558
Contingent consideration expense 28,197 - 37,287 -
Total operating costs and expenses 1,045,506 976,915 2,912,010 2,971,170
Operating income 12,008 183,369 522,885 460,309
Other income (expenses):
Gain (loss) on investments in equity securities, net (651 ) (14,129 ) (1,332 ) (4,201 )
Gain on acquisition of business - - 24,159 -
Other 616 (133 ) (2,419 ) 940
Investment income 4,544 11,793 14,038 40,015
Interest expense - (792 ) - (3,596 )
Total other income (expenses) 4,509 (3,261 ) 34,446 33,158
Income before income taxes 16,517 180,108 557,331 493,467
Provision for income taxes (522 ) (60,512 ) (158,276 ) (159,036 )
Net income $ 15,995 $ 119,596 $ 399,055 $ 334,431
Net income per share:
Basic $ 0.06 $ 0.44 $ 1.48 $ 1.25
Diluted (1) $ 0.06 $ 0.42 $ 1.45 $ 1.19
Weighted average shares outstanding:
Basic 268,957 269,176 269,923 267,767
Diluted (1) 273,741 288,179 275,375 286,003
All amounts herein are presented in accordance with GAAP and are
provided for quantitative analysis only and should be read in
conjunction with the text of the Earnings Release. In addition, we
believe that certain Non-GAAP financial measures, when considered
together with the GAAP figures, can enhance the overall
understanding of the company's past financial performance and its
prospects for the future. Please refer to our GAAP to Non-GAAP
Reconciliations attached to the Earnings Releases for the above
respective periods, which are filed as 8-K's with the Securities
and Exchange Commission at www.sec.gov.
The Non-GAAP financial measures are provided with the intent of
providing investors with a more complete understanding of the
trends underlying our operating results and financial position and
are among the primary indicators management uses for planning and
forecasting purposes and measuring the company's performance.
Please refer to our Form 10-Q's and Form 10-K's for an in-depth
discussion and analysis of our results of operations and financial
position and for detailed information regarding specific material
transactions in a particular period.
(1 ) Prior to January 1, 2009, in accordance with EITF 04-8, the shares
issuable upon conversion of our $690.0 million in principal of 1.25%
convertible senior notes were included in diluted weighted average
shares outstanding for purposes of computing diluted earnings per
share, unless the effect was anti-dilutive. Accordingly, interest
and debt fees related to these notes of $1.9 million, net of tax,
for the three months ended September 30, 2008, and $5.7 million, net
of tax, for the nine months ended September 30, 2008 have been added
back to net income, and approximately 9.7 million shares issuable
upon conversion of these notes, prior to redemption, have been
included in diluted weighted average shares outstanding. There are
no similar adjustments to the computation of diluted earnings per
share for the three and nine months ended September 30, 2009,
because the notes were redeemed, primarily for cash, on December 1,
2008.
GENZYME CORPORATION (GENZ)
Condensed Consolidated Balance Sheets September 30, December 31,
(Unaudited, amounts in thousands) 2009 2008
Cash and all marketable securities $ 988,872 $ 973,691
Other current assets 1,947,836 1,886,522
Property, plant and equipment, net 2,695,231 2,306,567
Intangibles, net 3,779,951 3,055,772
Other noncurrent assets 559,001 448,724
Total assets $ 9,970,891 $ 8,671,276
Current liabilities $ 1,097,440 $ 914,283
Noncurrent liabilities 1,258,120 451,000
Stockholders' equity 7,615,331 7,305,993
Total liabilities and stockholders' equity $ 9,970,891 $ 8,671,276
Genzyme Corporation (GENZ)
Analyst Schedule
(Unaudited, amounts in thousands, except percentage amounts)
Q3-09
vs.
Q3-08
Q3-08 Q4-08 Q1-09 Q2-09 Q3-09 % B/(W) FY 2007 FY 2008 YTD 09/30/09
Total revenues:
Genetic Diseases
Cerezyme $ 309,280 $ 306,034 $ 295,970 $ 298,087 $ 93,599 (70 %) $ 1,133,153 $ 1,238,977 $ 687,656
Fabrazyme 125,619 125,558 122,201 134,302 115,161 (8 %) 424,284 494,260 371,664
Myozyme 76,663 74,967 67,392 79,273 85,980 12 % 200,728 296,176 232,645
Aldurazyme 38,236 37,579 36,837 39,190 40,331 5 % - 151,664 116,358
Other Genetic Diseases 11,367 14,039 14,650 17,301 19,217 69 % 8,314 45,615 51,168
Total Genetic Diseases product and service revenue 561,165 558,177 537,050 568,153 354,288 (37 %) 1,766,479 2,226,692 1,459,491
R&D Revenue - - - - - 1,059 - -
Total Genetic Diseases 561,165 558,177 537,050 568,153 354,288 (37 %) 1,767,538 2,226,692 1,459,491
Cardiometabolic and Renal
Renagel and Renvela (including Sevelamer) 170,992 169,476 170,599 175,398 181,702 6 % 602,670 677,729 527,699
Hectorol 33,825 34,400 33,030 28,981 36,869 9 % 115,708 128,153 98,880
Subtotal 204,817 203,876 203,629 204,379 218,571 7 % 718,378 805,882 626,579
Thyrogen 38,153 37,062 38,826 42,860 41,691 9 % 113,587 148,448 123,377
Other Cardiometabolic and Renal 573 496 494 753 742 29 % 103 1,653 1,989
Total Cardiometabolic and Renal product and service revenue 243,543 241,434 242,949 247,992 261,004 7 % 832,068 955,983 751,945
R&D revenue 56 27 13 8 156 179 % 1,200 200 177
Total Cardiometabolic and Renal 243,599 241,461 242,962 248,000 261,160 7 % 833,268 956,183 752,122
Biosurgery
Synvisc 67,513 68,512 63,171 82,417 87,526 30 % 242,319 263,094 233,114
Sepra products 33,001 35,278 34,304 36,038 37,831 15 % 104,318 133,663 108,173
Other Biosurgery 21,787 20,908 21,485 20,002 19,643 (10 %) 74,673 91,698 61,130
Total Biosurgery product and service revenue 122,301 124,698 118,960 138,457 145,000 19 % 421,310 488,455 402,417
R&D revenue 661 563 562 870 647 (2 %) 5,337 2,645 2,079
Total Biosurgery 122,962 125,261 119,522 139,327 145,647 18 % 426,647 491,100 404,496
Hematologic Oncology
Total Hematologic Oncology product and service revenue 26,328 27,437 34,423 55,078 87,982 234 % 69,927 102,899 177,483
R&D revenue 7,726 15,104 8,775 5,918 7 (100 %) 18,601 36,148 14,700
Total Hematologic Oncology 34,054 42,541 43,198 60,996 87,989 158 % 88,528 139,047 192,183
Other
Genetic/Diagnostics product and service revenue 121,163 124,840 129,194 132,955 133,748 10 % 410,917 477,614 395,897
Transplant product and service revenue 47,784 50,723 52,666 56,060 55,604 16 % 174,826 192,200 164,330
Other product and service revenue 28,598 30,252 23,501 22,423 18,496 (35 %) 108,577 119,155 64,420
Total Other product and service revenue 197,545 205,815 205,361 211,438 207,848 5 % 694,320 788,969 624,647
R&D revenue 959 305 778 596 582 (39 %) 3,218 3,048 1,956
Total Other 198,504 206,120 206,139 212,034 208,430 5 % 697,538 792,017 626,603
Total revenues $ 1,160,284 $ 1,173,560 $ 1,148,871 $ 1,228,510 $ 1,057,514 (9 %) $ 3,813,519 $ 4,605,039 $ 3,434,895
All amounts herein are presented in accordance with GAAP and are
provided for quantitative analysis only and should be read in
conjunction with the text of the Earnings Release and our audited
financial statements filed with the Securities and Exchange
Commission. Please refer to our Form 10-Q's and Form 10-K's for an
in-depth discussion and analysis of our results of operations and
financial position and for detailed information regarding specific
material transactions in a particular period.
GENZYME CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP EARNINGS AND CASH GENERATED
For the Three Months Ended September 30, 2009
(Amounts in thousands, except percentage and per share data)
OTHER DISCRETE ITEMS
(included in GAAP and Non-GAAP results)
Bayer
GAAP Acquisition FAS 123R Allston Technology
As Reported Related Expense NON-GAAP (1) Remediation Purchase
Income Statement Classification:
Total revenues $ 1,057,514 $ 1,057,514
Cost of products and services sold $ (359,407 ) $ 17,740 $ 7,575 $ (334,092 ) $ 23,735
Gross margin 66 % $ 698,107 $ 17,740 $ 7,575 68 % $ 723,422 $ 23,735 $ -
Selling, general and administrative $ (367,347 ) $ 24,648 $ (342,699 )
Research and development $ (219,275 ) $ 14,058 $ (205,217 ) $ 7,000
Amortization of intangibles $ (71,280 ) $ (71,280 )
Contingent consideration expense $ (28,197 ) $ 28,197 $ -
Gains (losses) on investments in equity securities $ (651 ) $ (651 )
Gain on acquisition of business $ - $ -
Other $ 617 $ 617
Investment income $ 4,543 $ 4,543
Interest expense $ - $ -
Summary:
Income (loss) before income taxes $ 16,517 $ 45,937 $ 46,281 $ 108,735 $ 23,735 $ 7,000
(Provision for) benefit from income taxes 3.16 % $ (522 ) $ (11,646 ) $ (12,700 ) 22.87 % $ (24,868 ) $ (4,225 ) $ (1,574 )
Net income (loss) $ 15,995 $ 34,291 $ 33,581 $ 83,867 $ 19,510 $ 5,426
Net income (loss) per share:
Basic $ 0.06 $ 0.13 $ 0.12 $ 0.31 $ 0.07 $ 0.02
Diluted $ 0.06 $ 0.13 $ 0.12 $ 0.31 $ 0.07 $ 0.02
Weighted average shares outstanding:
Basic 268,957 268,957 268,957 268,957 268,957 268,957
Diluted 273,741 273,741 273,741 273,741 273,741 273,741
Notes:
(1) Represents the Non-GAAP results of operations for Genzyme
Corporation for the three months ended September 30, 2009. We
believe that certain Non-GAAP financial measures, when considered
together with the GAAP figures, can enhance the overall
understanding of the company's past financial performance and its
prospects for the future. The Non-GAAP financial measures are
included with the intent of providing investors with a more
complete understanding of the trends underlying our operating
results and financial position and are among the primary
indicators management uses for planning and forecasting purposes
and measuring the company's performance. Such Non-GAAP financial
measures should not be considered in isolation or used as a
substitute for GAAP. Earnings per share are calculated as net
income (loss) divided by weighted average shares outstanding.
Therefore, earnings per share may not add across due to rounding.
SOURCE: Genzyme Corp.
Genzyme Corp. Media Contact: Erin Emlock, 617-768-6923 or Investor Contact: Patrick Flanigan, 617-768-6563
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.